Meeting
2014 ASCO Annual Meeting
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
Authors
Vicky Makker
Memorial Sloan-Kettering Cancer Center, New York, NY
Vicky Makker , Virginia L. Filiaci , Lee-may Chen , Christopher Darus , James Erasmus Kendrick , Gregory Sutton , Katherine Moxley , Carol Aghajanian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01642082
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5594)
DOI
10.1200/jco.2014.32.15_suppl.5594
Abstract #
5594
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda
Poster
2017 ASCO Annual Meeting
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
First Author: Neesha C. Dhani
Poster
2014 ASCO Annual Meeting
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
First Author: Michelle Wilson
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee